Based on our results with our proprietary CD30 targeting ADC, we published an article in Bioconjugate Chemistry. We compared our technology McSAF Inside to maleimide used in Adcetris.
We showed an increased stability and relevant in vivo efficacy in a lymphoma mouse model while treatment was well tolerated in rats.
For more details, go check the article : Innovative Bioconjugation Technology for Antibody–Drug Conjugates: Proof of Concept in a CD30-Positive Lymphoma Mouse Model | Bioconjugate Chemistry (acs.org).
